Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Teva Pharmaceutical. The associated price target remains the same with $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Buy rating due to a combination of factors including Teva Pharmaceutical’s strategic focus and financial outlook. The company’s management has expressed confidence in achieving an investment-grade credit rating by the second half of 2026, which is expected to free up significant cash for redeployment. This financial stability, coupled with a focus on de-risked and synergistic business development, positions Teva well for future growth.
Additionally, Teva’s innovative product pipeline and strategic market positioning further support the Buy rating. The company is optimistic about its growth brands, particularly in the psychiatry and asthma markets, where it sees significant commercial opportunities. Despite potential macroeconomic headwinds, Teva’s management believes these can be managed within current guidance, reinforcing the company’s robust outlook.
In another report released yesterday, UBS also maintained a Buy rating on the stock with a $26.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TEVA in relation to earlier this year.